Search

Your search keyword '"Neoplasms, Unknown Primary/*drug therapy/mortality"' showing total 3 results
Start Over Descriptor "Neoplasms, Unknown Primary/*drug therapy/mortality"
3 results on '"Neoplasms, Unknown Primary/*drug therapy/mortality"'

1. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study

Author

Briassoulis, E. Ch, Fountzilas, George, Bamias, A. T., Dimopoulos, M. A., Xiros, N., Aravantinos, Gerasimos, Samantas, E., Kalofonos, H. P., Makatsoris, T., Mylonakis, N., Papakostas, P., Skarlos, Dimosthenis V., Varthalitis, I., Pavlidis, Nicholas, Pavlidis, Nicholas [0000-0002-2195-9961], Aravantinos, Gerasimos [0000-0002-2106-1713], and Kalofonos, H. P. [0000-0002-3286-778X]

Subjects
Oncology, Male, Survival rate, Neurologic disease, Organoplatinum Compounds, medicine.medical_treatment, Organoplatinum Compounds/administration & dosage/adverse effects/therapeutic use, Toxicology, Treatment response, Trial, Cancer growth, Multiple cycle treatment, derivatives/therapeutic use, Drug activity, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), Disease course, Liver metastasis, Depression, Unknown primary, Tumor localization, Prognosis, Multicenter study, Clinical trial, Oxaliplatin, Cancer of unknown primary, Adenocarcinoma/drug therapy/mortality/secondary, Granulocyte colony stimulating factor, Liver disease, Drug mechanism, Human, Diarrhea, medicine.medical_specialty, Clinical article, Febrile neutropenia, Weight reduction, Side effect, Adenocarcinoma, Irinotecan, Disease-Free Survival, Drug Administration Schedule, Article, Combination chemotherapy, Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse, Humans, Aged, Pharmacology, Cancer of unknown primary site, Bone metastasis, Leukopenia, medicine.disease, digestive system diseases, Regimen, Atropine, Cancer Research, Peripheral neuropathy, Medical decision making, Neoplasms, Nausea and vomiting, Middle aged, Organoplatinum compounds, Visceral metastasis, Fatigue, Priority journal, Drug tolerability, Drug withdrawal, Anemia, Middle Aged, Anorexia, Female, effects/*therapeutic use, Camptothecin/administration & dosage/adverse effects/analogs &, medicine.drug, Adult, Abdominal pain, Neutropenia, Cholinergic syndrome, Fever, Disease-free survival, Neoplasms, Unknown Primary/*drug therapy/mortality, Loperamide, Internal medicine, Antineoplastic combined chemotherapy protocols, Carcinoma, medicine, Chemotherapy, Phase 2 clinical trial, Disease severity, Antineoplastic activity, Blood cell count, business.industry, Drug administration schedule, Cancer, Thrombocytopenia, Cancer survival, Clinical feature, Neoplasms, Unknown Primary, Unknown-primary-carcinoma, Camptothecin, Phase-ii, business, Antiemetic agent, Controlled study, Constipation
Abstract

Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas. Methods: This was a multicenter phase-II trial. Protocol treatment consisted of oxaliplatin 80 mg/m2 followed by irinotecan 160 mg/m2 administered every 3 weeks. The primary end points were response rate and toxicity, and secondary end points were time to progression and survival. Results: Forty-seven patients with liver, bone or multiple visceral metastases entered into the trial and received a median 6 chemotherapy cycles (1-11). The regimen was very well tolerated with one febrile neutropenia case and six cases with diarrhea grade 3 (16%). In intent-to-treat analysis the tumor response rate was 13% (95% CI = 4.8-25.7%) and 12 patients (27%, 95%CI 13.9-40.4%) had at least 4 months' duration of disease stabilization. The median time to progression was 2.7 months and the median survival was 9.5 months, with 40% of patients alive at 1 year. Conclusions: The IROX regimen demonstrated similar efficacy and a favorable toxicity profile compared to other more toxic chemotherapy combinations in patients with poor-prognosis CUP. © 2007 Springer-Verlag. 62 2 277 284

Published
2008

2. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?

Author

Pentheroudakis, George, Briassoulis, E. Ch, Karavasilis, V., Fountzilas, George, Xeros, N., Samelis, G., Samantas, E., Pavlidis, Nicholas, Pavlidis, Nicholas [0000-0002-2195-9961], Pentheroudakis, George [0000-0002-6632-2462], and Karavasilis, V. [0000-0002-5806-9399]

Subjects
Male, Ca 125 antigen, medicine.medical_treatment, Cancer regression, Bridged compounds, Cancer growth, Cancer risk, Neoplasms, Carcinomatous peritonitis, Antineoplastic agents, 80 and over, Bridged Compounds/administration & dosage, Tumor regression, Lymph node, Peritoneal Neoplasms, Priority journal, Aged, 80 and over, Greece, Unknown primary, Combination chemotherapy, Hematology, General Medicine, Middle Aged, Debulking, Peritoneal Neoplasms/*drug therapy/mortality/secondary, Prognosis, Antineoplastic Agents/administration & dosage, medicine.anatomical_structure, Taxoids/administration & dosage, Treatment Outcome, Oncology, Tumor markers, Lymphatic Metastasis, Adenocarcinoma, Taxoids, Female, Cancer chemotherapy, Human, Bridged-Ring Compounds, Adult, medicine.medical_specialty, Carcinoma/*drug therapy/mortality, Antineoplastic Agents, Major clinical study, Adenocarcinoma/*drug therapy/mortality, Neoplasms, Unknown Primary/*drug therapy/mortality, Article, Cancer of unknown primary, Median follow-up, Biomarkers, Tumor, Carcinoma, medicine, Humans, Radiology, Nuclear Medicine and imaging, Survival analysis, Platinum, Ca 19-9 antigen, Aged, Proportional Hazards Models, Undifferentiated carcinoma, Lymph node metastasis, Chemotherapy, business.industry, Taxane derivative, Biological, medicine.disease, Survival Analysis, Cancer survival, Surgery, Peritoneal neoplasms, Tumor Markers, Biological/blood, Neoplasms, Unknown Primary, business, Follow-Up Studies
Abstract

Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases (n =33) or peritoneal carcinomatosis (n = 47) were analysed retrospectively. The majority had poorly differentiated adenocarcinoma or undifferentiated carcinoma, treated with platinum-taxane based chemotherapy from 1996 till 2002. Females with peritoneal carcinomatosis also underwent surgical debulking. Objective tumour regression was present in 44% of patients (nodal group 30% versus peritoneal group 53%, p=0.066). Complete responses were seen more often in peritoneal carcinomatosis patients (nodal group 9%, peritoneal group 36%, p = 0.008). At a median follow up of 60 months, median progression-free and overall survival were 5 and 10 months respectively in the nodal group, 7 and 15 months in the peritoneal group. Five-year survival was 7% (nodal group 0% vs. peritoneal group 10%, p = 0.05). Complete responders fared better than non-CR patients. Fewer than four metastatic sites, elevated CA 125, and normal CA 19-9 levels were favourable prognostic factors for survival. Modern combination chemotherapy has satisfactory activity, with a minority of CUP patients enjoying long-term responses. Research efforts towards complete remission consolidation and molecular profiling are imperative. © 2005 Taylor & Francis. 44 2 155 160

Published
2005

3. Evaluation of six tumor markers in patients with carcinoma of unknown primary

Author

Pavlidis, Nicholas, Kalef-Ezra, J. A., Briassoulis, E. Ch, Skarlos, Dimosthenis V., Kosmidis, Paraskevas A., Saferiadis, K., Bairaktari, Eleni Th, Bafaloukos, Dimitrios, Maravegias, A., Theoharis, D., Fountzilas, George, and Pavlidis, Nicholas [0000-0002-2195-9961]

Subjects
Male, Cancer Research, Pathology, Tumor Markers, Biological/*blood, Lung Neoplasms, Bone Neoplasms/secondary, Cancer localization, Ca 125 antigen, medicine.medical_treatment, Ca 15-3 antigen, Chorionic Gonadotropin, Gastroenterology, Peritoneal Neoplasms/secondary, Central Nervous System Neoplasms, Carcinoembryonic antigen, Lung neoplasms, Liver neoplasms, Neoplasms, Adenocarcinoma/secondary, Medicine, Carcinoma/secondary, Liver metastasis, Chorionic gonadotropin beta subunit, Peritoneal Neoplasms, Priority journal, Antigens, Tumor-Associated, Carbohydrate/blood, biology, Unknown primary, Liver Neoplasms, Bone neoplasms, Middle Aged, Prognosis, Middle age, Chorionic gonadotropin, Survival Rate, Alpha-fetoproteins, Oncology, Liver Neoplasms/secondary, Tumor markers, Adenocarcinoma, Female, alpha-Fetoproteins, Gonadotropin, Carcinoembryonic Antigen/blood, Oncofetal antigen, Human, Adult, Carbohydrate, medicine.medical_specialty, medicine.drug_class, Neoplasms, Unknown Primary/*blood/drug therapy/mortality, Central Nervous System Neoplasms/secondary, CA 15-3, Bone Neoplasms, Major clinical study, Article, Carcinoma of unknown primary, Antigens, Neoplasm, Predictive Value of Tests, Advanced cancer, Internal medicine, Biomarkers, Tumor, Carcinoma, Humans, Antigens, Tumor-Associated, Carbohydrate, Serum tumor markers, Antigens, Antigens, Neoplasm/*blood, Lung Neoplasms/secondary, Antigen expression, Ca 19-9 antigen, Retrospective Studies, Undifferentiated carcinoma, Lymph node metastasis, Alpha fetoprotein, Chemotherapy, Epithelioma, business.industry, Biological, medicine.disease, Cancer survival, Carcinoembryonic Antigen, Peritoneal neoplasms, Central nervous system neoplasms, Pediatrics, Perinatology and Child Health, Tumor-associated, biology.protein, Linear Models, Neoplasm, Neoplasms, Unknown Primary, Chorionic Gonadotropin/blood, Lymph Nodes, alpha-Fetoproteins/analysis, business
Abstract

We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and α‐fetoprotein (AFP) were related with the histological pattern (undifferentiated carcinoma or adenocarcinoma), the number and the site of metastases, as well as the response to chemotherapy and the patients' survival. More than 40% of the patients had increased serum levels of all six tumor markers, except of AFP which was found to be increased in only 17% of them. Increased levels of CA 19‐9 were related to metastatic adenocarcinoma, whereas CA 19‐9 and CA 15‐3 had a relationship with more advanced disease. Patients with liver involvement had higher mean levels of CEA and CA 19‐9 as compared to those with nodal disease. None of these markers was found to have a predictive value for response to chemotherapy or survival. Although the present study has a retrospective nature, it allows us to conclude that patients with CUP have a nonspecific over‐expression of the above serum tumor markers and that routine use of these markers does not offer any diagnostic or prognostic assistance. © 1994 wiley‐Liss, lnc. Copyright © 1994 Wiley‐Liss, Inc., A Wiley Company 22 3 162 167

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results